Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3. This molecule is intended for the treatment of recurrent or refractory multiple myeloma (MM), an indication for which it has previously received clinical clearance in the US.
SIM0500 is considered a potential best-in-class treatment for MM, based on pre-clinical data. Developed through Simcere’s proprietary T cell adapter multi-specific antibody drug development platform, SIM0500 combines the company’s own low-affinity, high-targeted activation CD3 antibody with antibodies against tumor-related antigens. The drug has demonstrated advantages such as excellent tumor-killing effects and good tolerability, positioning it as a promising candidate for MM treatment.- Flcube.com
